Lead Product(s) : Cholic Acid
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Mirum Pharmaceuticals
Deal Size : $445.0 million
Deal Type : Divestment
Details : Under the agreement, Mirum will purchase Travere’s bile acid product portfolio including, Cholbam, indicated for the treatment of bile acid synthesis disorders and Chenodal, indicated for the treatment of radiolucent stones in the gallbladder.
Product Name : Cholbam
Product Type : Other Small Molecule
Upfront Cash : $210.0 million
July 17, 2023
Lead Product(s) : Cholic Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Mirum Pharmaceuticals
Deal Size : $445.0 million
Deal Type : Divestment
Lead Product(s) : Cholic Acid
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Ethypharm
Deal Size : Undisclosed
Deal Type : Agreement
Ethypharm, CTRS Partner to Register Orphacol® in China
Details : Under the agreement, CTRS has granted Ethypharm exclusive rights to distribute Orphacol (cholic acid) in China. It is indicated for the two rare inborn errors of primary bile acid synthesis.
Product Name : Orphacol
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 11, 2020
Lead Product(s) : Cholic Acid
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Ethypharm
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
